Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$3.88+0.06 (+1.57%)
Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –
Arbutus Biopharma cash
Cash and short-term investments held at the end of each period.
Arbutus Biopharma's cash was $337.49M at Sep 30, 2026. For fiscal 2025 it was $91.50M, down 25.4% from the year before. Over ten years it grew -6.6% a year on average. The highest annual figure on record is $191.00M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.50M | -25.4% |
| FY2024 | Dec 31, 2024 | $122.60M | -7.3% |
| FY2023 | Dec 31, 2023 | $132.30M | -28.2% |
| FY2022 | Dec 31, 2022 | $184.30M | -3.5% |
| FY2021 | Dec 31, 2021 | $191.00M | +54.9% |
| FY2020 | Dec 31, 2020 | $123.30M | +35.7% |
| FY2019 | Dec 31, 2019 | $90.83M | -27.1% |
| FY2018 | Dec 31, 2018 | $124.62M | -1.4% |
| FY2017 | Dec 31, 2017 | $126.35M | -3.2% |
| FY2016 | Dec 31, 2016 | $130.56M | -28.0% |
| FY2015 | Dec 31, 2015 | $181.30M | +61.6% |
| FY2014 | Dec 31, 2014 | $112.16M | +163121.6% |
| FY2013 | Dec 31, 2013 | $68.72K | -99.9% |
| FY2012 | Dec 31, 2012 | $47.02M | +420.7% |
| FY2011 | Dec 31, 2011 | $9.03M | -27.2% |
| FY2010 | Dec 31, 2010 | $12.41M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $337.49M | +260.2% |
| Q2 FY2026 | Jun 30, 2026 | $92.63M | -5.6% |
| Q1 FY2026 | Mar 31, 2026 | $95.23M | -15.5% |
| Q4 FY2025 | Dec 31, 2025 | $91.50M | -25.4% |
| Q3 FY2025 | Sep 30, 2025 | $93.70M | -26.7% |
| Q2 FY2025 | Jun 30, 2025 | $98.09M | -30.9% |
| Q1 FY2025 | Mar 31, 2025 | $112.71M | -12.8% |
| Q4 FY2024 | Dec 31, 2024 | $122.60M | -7.3% |
| Q3 FY2024 | Sep 30, 2024 | $127.79M | -4.8% |
| Q2 FY2024 | Jun 30, 2024 | $141.99M | -6.9% |
| Q1 FY2024 | Mar 31, 2024 | $129.24M | -11.9% |
| Q4 FY2023 | Dec 31, 2023 | $132.30M | -28.2% |
| Q3 FY2023 | Sep 30, 2023 | $134.18M | -0.4% |
| Q2 FY2023 | Jun 30, 2023 | $152.48M | -24.0% |
| Q1 FY2023 | Mar 31, 2023 | $146.73M | -33.8% |
| Q4 FY2022 | Dec 31, 2022 | $184.30M | -3.5% |
| Q3 FY2022 | Sep 30, 2022 | $134.72M | -11.3% |
| Q2 FY2022 | Jun 30, 2022 | $200.60M | +65.4% |
| Q1 FY2022 | Mar 31, 2022 | $221.80M | +68.0% |
| Q4 FY2021 | Dec 31, 2021 | $191.00M | +54.9% |
| Q3 FY2021 | Sep 30, 2021 | $151.90M | +28.4% |
| Q2 FY2021 | Jun 30, 2021 | $121.30M | +47.2% |
| Q1 FY2021 | Mar 31, 2021 | $132.00M | +399.7% |
| Q4 FY2020 | Dec 31, 2020 | $123.30M | +35.7% |
| Q3 FY2020 | Sep 30, 2020 | $118.30M | +31.3% |
| Q2 FY2020 | Jun 30, 2020 | $82.39M | -13.5% |
| Q1 FY2020 | Mar 31, 2020 | $26.42M | -76.1% |
| Q4 FY2019 | Dec 31, 2019 | $90.83M | -27.1% |
| Q3 FY2019 | Sep 30, 2019 | $90.08M | -36.6% |
| Q2 FY2019 | Jun 30, 2019 | $95.28M | -38.5% |
| Q1 FY2019 | Mar 31, 2019 | $110.59M | -35.9% |
| Q4 FY2018 | Dec 31, 2018 | $124.62M | -1.4% |
| Q3 FY2018 | Sep 30, 2018 | $142.02M | +61.1% |
| Q2 FY2018 | Jun 30, 2018 | $154.87M | +50.3% |
| Q1 FY2018 | Mar 31, 2018 | $172.54M | +56.3% |
| Q4 FY2017 | Dec 31, 2017 | $126.35M | -3.2% |
| Q3 FY2017 | Sep 30, 2017 | $88.18M | – |
| Q2 FY2017 | Jun 30, 2017 | $103.01M | – |
| Q1 FY2017 | Mar 31, 2017 | $110.38M | – |
| Q4 FY2016 | Dec 31, 2016 | $130.56M | – |
See a number that looks wrong?